Terrazzino, Salvatore <br/><br/>
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.  [electronic resource] 

 -  Pharmacogenetics and genomics  Nov 2006 
 - 817-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-6872 
<br/><br/><label>Standard No.: </label>10.1097/01.fpc.0000230412.89973.c0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--diagnosis<br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Chemotherapy, Adjuvant<br/>Combined Modality Therapy<br/>Female<br/>Fluorouracil--therapeutic use<br/>Genotype<br/>Haplotypes<br/>Humans<br/>Male<br/>Methylenetetrahydrofolate Reductase (NADPH2)--genetics<br/>Middle Aged<br/>Neoplasm Staging<br/>Polymorphism, Genetic<br/>Prognosis<br/>Radiation Dosage<br/>Radiotherapy, Adjuvant<br/>Rectal Neoplasms--diagnosis<br/>Remission Induction